IDRA Idera Pharmaceuticals Inc.

2.54
-0.11  -4%
Previous Close 2.65
Open 2.67
Price To Book 0.92
Market Cap 68959303
Shares 27,181,436
Volume 58,985
Short Ratio
Av. Daily Volume 366,550

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19576546
  2. 8-K - Current report 19518322
  3. 8-K - Current report 19512184
  4. 8-K - Current report 181240684
  5. 8-K - Current report 181234550

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 final data due 2H 2019.
Tilsotolimod + ipilimumab - ILLUMINATE 204
Cancer - melanoma
Development suspended - September 2016.
IMO-8400
Waldenström’s Macroglobulinemia
Development suspended - September 2016.
IMO-8400
Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 data released June 12, 2018 - primary endpoint not met.
IMO-8400
Dermatomyositis
Phase 1 trial is ongoing.
Tilsotolimod and pembrolizumab
Solid tumors
Phase 1b trial is ongoing. Data due 2019.
Tilsotolimod - ILLUMINATE 101
Solid tumors
Phase 3 completion of enrolment due YE 2019.
Tilsotolimod (IMO-2125) + ipilimumab - ILLUMINATE 301
Melanoma

Latest News

  1. Idera acquires Travis CI
  2. How Much is Idera Pharmaceuticals, Inc.’s (NASDAQ:IDRA) CEO Getting Paid?
  3. Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
  4. Idera Pharmaceuticals Announces Appointment of Carol A. Schafer to its Board of Directors
  5. Today's Research Reports on Trending Tickers: Johnson & Johnson and Idera Pharmaceuticals
  6. Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
  7. Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018
  8. United Parcel Service, Endurance International Group, Idera Pharmaceuticals, Aptevo Therapeutics, and Electro Scientific Industries — Future Expectations, Projections Moving into 2018
  9. The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
  10. How Many Idera Pharmaceuticals Inc (NASDAQ:IDRA) Shares Do Institutions Own?
  11. Idera Pharmaceuticals (IDRA) Reports Q3 Loss, Lags Revenue Estimates
  12. Idera: 3Q Earnings Snapshot
  13. vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session
  14. What does Idera Pharmaceuticals Inc’s (NASDAQ:IDRA) Balance Sheet Tell Us About Its Future?

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19576546
  2. 8-K - Current report 19518322
  3. 8-K - Current report 19512184
  4. 8-K - Current report 181240684
  5. 8-K - Current report 181234550
  6. 8-K - Current report 181201498
  7. 424B5 - Prospectus [Rule 424(b)(5)] 181201488
  8. 8-K - Current report 181163817
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181163216
  10. 8-K - Current report 181155564